Investigational drug · Phase 3
TQB3454
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Solid Tumors, Biliary Carcinoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Jul 31, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
5
Any phase or sponsor naming "TQB3454"
First trial start
2023
Sep 21, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TQB3454", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Solid Tumors
- Biliary Carcinoma
Approved drugs for the same conditions: Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "TQB3454" as an intervention, largest first.
- A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma.Pivotal-lookingActive, not recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT05987358 · 165 participants (planned) · Start Sep 21, 2023 · Primary completion Dec 2026
Drug: TQB3454 tablets; TQB3454 tablets matching placebo · For: Biliary Carcinoma
Sites: Beijing, China; Lanzhou, China; Tangshan, China · 6 sites in all
- Clinical Trial Evaluating the Efficacy and Safety of TQB3454 Tablets in Participants With Advanced Solid TumorsNot yet recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT07738679 · 127 participants (planned) · Start Jul 2026 · Primary completion Dec 2028
Drug: TQB3454 tablets · For: Advanced Solid Tumors
Sites: Beijing, China; Lanzhou, China; Guangzhou, China · 22 sites in all
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT04481607 · 96 participants (planned) · Start Aug 24, 2020 · Primary completion Dec 31, 2022
Drug: TQB3454 · For: Advanced Solid Tumor or Hematologic Tumor
Sites: Beijing, China; Xuzhou, China; Tianjin, China · 5 sites in all
- A Study of TQB3454 Tablets in Patients With Blood TumorsStatus unknown
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT06218771 · 80 participants (planned) · Start Jul 10, 2023 · Primary completion Jun 2025
Drug: TQB3454 Tablets · For: Acute Myeloid Leukemia; Myelodysplastic Syndromes
Sites: Bengbu, China; Cangzhou, China; Chengde, China · 17 sites in all
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT06139367 · 40 participants (planned) · Start Nov 2023 · Primary completion Dec 2023
Drug: TQB3454 tablets · For: Biliary Carcinoma
Sites: Qingdao, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced Solid Tumors
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- AdabelimumabSHR-A2102, SHR2554Phase 320 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- SYS6010Phase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.